SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000886163-24-000029
Filing Date
2024-05-07
Accepted
2024-05-07 16:03:28
Documents
15
Period of Report
2024-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lgnd-20240507.htm   iXBRL 8-K 25679
2 EX-99.1 q12024earningsrelease_ex991.htm EX-99.1 166680
6 newligandlogo.jpg GRAPHIC 11718
  Complete submission text file 0000886163-24-000029.txt   351507

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lgnd-20240507.xsd EX-101.SCH 1911
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lgnd-20240507_lab.xml EX-101.LAB 21880
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lgnd-20240507_pre.xml EX-101.PRE 12518
18 EXTRACTED XBRL INSTANCE DOCUMENT lgnd-20240507_htm.xml XML 2728
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 24921698
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)